14 mars 2022
Allogeneic mesenchymal stromal cell transplantation may be a feasible approach for SSc
A single infusion of allogeneic bone marrow-derived mesenchymal stromal cells (MSCs) was well tolerated and showed preliminary efficacy for severe diffuse systemic sclerosis (SSc) in a phase 1/2 proof-of-concept study by Dominique Farge (Hôpital St-Louis, Paris, France) and colleagues.